The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - ARTbio; Convergent Therapeutics; Fusion Pharmaceuticals; Lilly; Pfizer; Ratio Therapeutics; Telix Pharmaceuticals
Consulting or Advisory Role - Advanced Accelerator Applications; ARTbio; AstraZeneca; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Fusion Pharmaceuticals; Isotopen Technologien; Janssen; Merck; Moyvant; Myriad Pharmaceuticals; Noria Therapeutics; Northstar Medical radioisotopes; Novartis; Pfizer; POINT Biopharma; Sanofi; Telix Pharmaceuticals; TeneoBio
Research Funding - Advanced Accelerator Applications (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Endocyte (Inst); Invitae (Inst); Janssen (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Progenics (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Lantheus Medical Imaging; Northstar Medical radioisotopes; Novartis
Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.
 
Johann S. De Bono
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; ImCheck therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics (Inst); Boehringer Ingelheim (Inst); CellCentric; Crescendo Biologics (Inst); Daiichi Sankyo; Dark Blue Therapeutics (Inst); Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon therapeutics; ImCheck therapeutics; Immunic Therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; MetaCurUm; Myricx Pharma; Novartis; Nurix (Inst); Oncternal Therapeutics; Orion; Pfizer (Inst); Qiagen; Sanofi Aventis GmbH (Inst); Sierra Oncology; Taiho Oncology; Takeda (Inst); Tango Therapeutics (Inst)
Speakers' Bureau - AstraZeneca
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); CellCentric (Inst); Crescendo Biologics (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Harpoon (Inst); Immunic Therapeutics (Inst); Janssen (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MetaCurUm (Inst); Myricx (Inst); Nurix (Inst); Oncternal Therapeutics (Inst); Orion (Inst); Pfizer (Inst); Sanofi Aventis GmbH (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; Cellcentric; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Halda Therapeutics; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Ambrx; Arvinas; AstraZeneca; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clarity Pharmaceuticals; Convergent Therapeutics; Core Medica; Curium Pharma; Daiichi; Exelixis; Flare Therapeutics; Fusion Pharmaceuticals; ITM Isotope Technologies Munich; Lantheus Medical Imaging; Mashup Media; Pfizer; POINT Biopharma; Progenics; Telix Pharmaceuticals; Transtherabio; Z-Alpha
Research Funding - Astellas Pharma (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Janssen (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; APCCC; AstraZeneca; Memorial Sloan-Kettering Cancer Center
Other Relationship - Novartis
(OPTIONAL) Uncompensated Relationships - Amgen; Amgen; Bayer; Janssen Oncology; Novartis
 
Oliver Sartor
No Relationships to Disclose
 
Xiao X. Wei
Honoraria - OncLive
Consulting or Advisory Role - Novartis; Novartis; Novartis
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Corvus Pharmaceuticals
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst)
Consulting or Advisory Role - Amgen (Inst); Arvinas; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CureVac; Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); Macrogenics; MSD (Inst); Novartis (Inst); Orion; Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; MSD; Pfizer
 
Ken Herrmann
Leadership - Pharma15; SOFIE; Theragnostics
Stock and Other Ownership Interests - AdvanCell; Aktis Oncology; Convergent Therapeutics; Pharma15; SOFIE; Theragnostics
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; AstraZeneca; Bain Capital; Bayer; Boston Scientific; BTG; Debiopharm Group; Fusion Pharmaceuticals; GE Healthcare; Immedica; IPSEN; ITG (Inst); Janssen Oncology; Molecular Partners; Novartis; Radiopharm Theranostics; ROTOP Pharmaka (Inst); Siemens Healthineers; Telix Pharmaceuticals
 
Josep M. Piulats
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Clovis Oncology; IDEAYA Biosciences; Immunocore; Janssen Oncology; Merck Sharp & Dohme; Pfizer; Roche/Genentech; VCN Biosciences
Research Funding - AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Immunocore; Incyte; Janssen Oncology; Merck Sharp & Dohme; Mirati Therapeutics; Pfizer/EMD Serono
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Janssen Oncology; Pfizer; Roche
 
Hakim Mahammedi
Honoraria - AAA/Endocyte/Novartis; Astellas Pharma; AstraZeneca; Bayer Schering Pharma; BMS; Janssen-Cilag; MSD Oncology; Novartis; Pfizer
Consulting or Advisory Role - Bayer; BMS
Travel, Accommodations, Expenses - Janssen-Cilag; Pfizer
 
Christopher Logothetis
Honoraria - AADi; Amgen; Boehringer Pharma GmbH; Janssen Scientific Affairs
Research Funding - Aragon Pharmaceuticals (Inst); Janssen; Novartis (Inst); ORIC Pharmaceuticals (Inst)
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - American Association for Cancer Research; AstraZeneca; Aveo; Axess Oncology; Bayer; Eisai; EMD Serono; Exelixis; IDEOlogy Health; Janssen Oncology; Medscape; Merck; Millennium Medical Publishing; Myovant Sciences; Nektar; Novartis; OncLive; Pfizer; Propella Therapeutics; Sanofi; Seagen; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Novartis; Pfizer; Physicans' Education Resource; Propella Therapeutics; RevHealth; Sanofi; Xcures
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Expert Testimony - Exelixis
Travel, Accommodations, Expenses - Bayer; Exelixis; Novartis; Pfizer
 
Lamis K. Eldjerou
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Connie Wong
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Patents, Royalties, Other Intellectual Property - Novartis
 
Louise Barys
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Nisha Rajagopal
Employment - LifeMine Therapeutics; LifeMine Therapeutics (I); SERVIER; SERVIER (I); Syros Pharmaceuticals; Syros Pharmaceuticals (I)
Stock and Other Ownership Interests - LifeMine Therapeutics; LifeMine Therapeutics (I); Syros Pharmaceuticals; Syros Pharmaceuticals (I)
Patents, Royalties, Other Intellectual Property - Syros Pharmaceuticals
Travel, Accommodations, Expenses - LifeMine Therapeutics; LifeMine Therapeutics (I); SERVIER; SERVIER (I); Syros Pharmaceuticals; Syros Pharmaceuticals (I)
Other Relationship - SERVIER; SERVIER (I); Syros Pharmaceuticals; Syros Pharmaceuticals (I)
 
Theodoulos Rodosthenous
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
 
Kim N. Chi
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BMS GmbH & Co. KG; BMS GmbH & Co. KG; Janssen; Merck; Novartis; Pfizer; POINT Biopharma; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; POINT Biopharma; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)